Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser procedure could offer new hope for pseudoexfoliation glaucoma patients

NCT ID NCT07401290

Disease control Sponsor: Vance Thompson Vision Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a non-invasive laser procedure called direct selective laser trabeculoplasty (DSLT) in 40 adults with pseudoexfoliation glaucoma. The goal is to see if the laser can safely lower eye pressure by at least 20% at 6 and 12 months. Participants will have their eye pressure measured after stopping any glaucoma medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Direct selective laser trabeculoplasty (DSLT) - a non-invasive laser procedure to improve fluid drainage in the eye
What this could lead to
If successful, this laser treatment could offer a safe, non-drug option to control eye pressure in people with pseudoexfoliation glaucoma.
What could go wrong
This is a small, early-stage study with only 40 participants and no comparison group. The results may not apply to all patients, and the procedure may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients diagnosed with pseudoexfoliation glaucoma (PXFG), with optic neuropathy consistent with glaucomatous damage of any severity * Open iridocorneal angle by gonioscopy, defined as a Shafer Grade II or greater * Treatment naive, or washed out IOP ranging from ≥18-35 mmHg * Able to complete medication washout safely and all follow-up visits * Participants must have a best correct visual acuity of 20/40 or better in the study eye(s), be able to undertake a reliable Humphrey visual field (HVF) (defined as fixation losses, false positives and false negatives less than 33%), and must have field loss no worse than -20 dB in treatment eye Exclusion Criteria: * Any contraindication to SLT or unable to have DSLT * Angle closure glaucoma or any other types of glaucoma other than PXFG * Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye * Any prior refractive surgery * H/o LPI within last 6 months * A history of any significant cataract required during study duration or cataract surgery in the last 6 months * Prior laser trabeculoplasty (ALT/SLT) * History of ocular inflammation and infection * Patients who are pregnant or have any clinically relevant systemic disease that may prevent them from reliably completing follow-up visits * Vulnerable populations that cannot provide proper informed consent will not be enrolled, such as children, prisoners, handicapped, or mentally disabled persons, or economically or educationally disadvantaged persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pseudoexfoliation glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exfoliation syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pseudoexfoliation glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Vance Thompson Vision

    Alexandria, Minnesota, 56308, United States

  • Vance Thompson Vision

    Omaha, Nebraska, 68137, United States

  • Vance Thompson Vision

    Fargo, North Dakota, 58078, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.